These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9055988)

  • 1. Reversible fluconazole resistance in Candida albicans: a potential in vitro model.
    Calvet HM; Yeaman MR; Filler SG
    Antimicrob Agents Chemother; 1997 Mar; 41(3):535-9. PubMed ID: 9055988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.
    Franz R; Kelly SL; Lamb DC; Kelly DE; Ruhnke M; Morschhäuser J
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3065-72. PubMed ID: 9835492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
    Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
    J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
    Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
    J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India.
    Mane A; Vidhate P; Kusro C; Waman V; Saxena V; Kulkarni-Kale U; Risbud A
    Mycoses; 2016 Feb; 59(2):93-100. PubMed ID: 26648048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [25S rDNA genotype and antifungal susceptibility of vaginal Candida albicans].
    Zhang X; Liu ZH
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):279-84. PubMed ID: 27116986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans.
    Najvar LK; Correa A; James P; Luther MF; Graybill JR
    J Antimicrob Chemother; 1996 Oct; 38(4):671-7. PubMed ID: 8937961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.
    Marr KA; Lyons CN; Ha K; Rustad TR; White TC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):52-9. PubMed ID: 11120944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
    Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
    Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?
    Graybill JR; Najvar LK; Holmberg JD; Correa A; Luther MF
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2197-200. PubMed ID: 8619566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients.
    Maebashi K; Niimi M; Kudoh M; Fischer FJ; Makimura K; Niimi K; Piper RJ; Uchida K; Arisawa M; Cannon RD; Yamaguchi H
    J Antimicrob Chemother; 2001 May; 47(5):527-36. PubMed ID: 11328762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in transcription factor Mrr2p contribute to fluconazole resistance in clinical isolates of Candida albicans.
    Wang Y; Liu JY; Shi C; Li WJ; Zhao Y; Yan L; Xiang MJ
    Int J Antimicrob Agents; 2015 Nov; 46(5):552-9. PubMed ID: 26404130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.
    Andes D; Lepak A; Nett J; Lincoln L; Marchillo K
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2384-94. PubMed ID: 16801416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance genes and trailing growth in Candida albicans isolates.
    Lee MK; Williams LE; Warnock DW; Arthington-Skaggs BA
    J Antimicrob Chemother; 2004 Feb; 53(2):217-24. PubMed ID: 14688046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of the expression levels of efflux pumps in fluconazole-resistant Candida albicans isolates].
    Gulat S; Doluca Dereli M
    Mikrobiyol Bul; 2014 Apr; 48(2):325-34. PubMed ID: 24819270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on experimental induction of fluconazole resistance in Candida albicans].
    Zhu YN; Lu SM
    Shi Yan Sheng Wu Xue Bao; 2004 Oct; 37(5):418-22. PubMed ID: 15636370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction.
    Shen H; An MM; Wang de J; Xu Z; Zhang JD; Gao PH; Cao YY; Cao YB; Jiang YY
    Biol Pharm Bull; 2007 Jan; 30(1):68-73. PubMed ID: 17202662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
    Borst A; Raimer MT; Warnock DW; Morrison CJ; Arthington-Skaggs BA
    Antimicrob Agents Chemother; 2005 Feb; 49(2):783-7. PubMed ID: 15673768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.